Evidence map›Paper›PMID 26436751›Full record

ArticleJAMA internal medicine2015

Selecting the Optimal Design for Drug Discontinuation Trials in a Setting of Advanced, Life-Limiting Illness-Reply.

Jean S Kutner, Christine S Ritchie, Amy P Abernethy

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in JAMA internal medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Jean S KutnerDepartment of Medicine, University of Colorado School of Medicine, Aurora.
Christine S RitchieSan Francisco Veterans Affairs Medical Center, Center for Research on Aging at the Jewish Home of San Francisco, San Francisco, California3Division of Geriatrics, Department of Medicine, University of California, San Francisco, San Francisco.
Amy P AbernethyCenter for Learning Health Care, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.

Funding

Refinement and Expansion of the Palliative Care Research Cooperative Group (PCRC)U24NR014637 · NINR · DUKE UNIVERSITY · PI KUTNER, JEAN S, POLLAK, KATHRYN I · 2013 to 2017
$9.6M
Creation and demonstration of a palliative care research cooperative groupUC4NR012584 · NINR · DUKE UNIVERSITY · PI ABERNETHY, AMY P., KUTNER, JEAN S · 2010 to 2010
$7.2M
NINR NIH HHS U24 NR014637NINR NIH HHS U24-NR014637NINR NIH HHS UC4-NR012584
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cardiovascular DiseasesCognition DisordersNeoplasmsFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMalePalliative CareHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID26436751

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.